AstraZeneca PLC said on Monday that the sale of its commercial rights to the Atacand hypertension management agent to the German pharmaceutical company Cheplapharm Arzneimittel GmbH had been completed for $ 400 million.
The British-Swedish pharmaceutical division said it had already received an amount of $ 250 million as part of the sale, and that it would receive another $ 150 million during the first half of 2021.
The company said Atacand and Atacand Plus made a pre-tax profit of $ 89 million in 2019 in the 70 countries covered by the purchase agreement.
The drug was developed in collaboration with Takeda Pharmaceutical Co. and each company in certain countries had exclusive rights to the medicine.
Write to Jaime Llinares Taboada at [email protected]; @JaimeLlinaresT